COMPANY OVERVIEW

NGM Bio is a research-driven, clinical-stage biopharmaceutical company that has generated a promising pipeline of therapeutics addressing cardio-metabolic and liver diseases.

---

LOCATION

South San Francisco, CA, USA

---

THERAPEUTIC AREAS

Metabolic Disorders

Oncology

---

WEBSITE

https://www.ngmbio.com

---

CAREER WEBSITE

https://www.ngmbio.com/careers/#SilkroadFrame

---

SOCIAL MEDIA

---

INVESTORS

---

---

PRESS RELEASES

Mar 20, 2019

NGM Bio Appoints Hsiao D. Lieu, M.D. as SVP, Chief Medical Officer and Alex DePaoli, M.D. to New Role of SVP, Chief Translational Officer

Mar 20, 2019

Merck and NGM Bio Announce Extension of Broad, Multi-Year Strategic Collaboration to 2022

Jan 3, 2019

Merck Exercises Option for NGM Bio’s Investigational Insulin Sensitizer, NGM313, for the Treatment of NASH and Type 2 Diabetes

Nov 12, 2018

NGM Bio Announces Preliminary Results from Phase 1b Study of NGM313 in Obese, Insulin Resistant Subjects with Nonalcoholic Fatty Liver Disease (NAFLD)

Nov 9, 2018

NGM Bio Announces New Histology Data from Phase 2 Trial of NGM282 in Patients with NASH

For More Press Releases

---